押注9亿人减重药市场,巨头开始瞄准中国创新疗法

第一财经
25 Mar

当地时间3月24日,诺和诺德称已获得港股上市药企联邦制药(3933.HK)子公司联邦生物科技减肥候选药物UBT251的全球开发、生产和销售权,诺和诺德将支付2亿美元的预付款,以及高达18亿美元的里程碑款项,潜在交易价值高达20亿美元。联邦制药最新公布的2024年财报显示,公司全年营收137.6亿元。3月25日收盘,联邦制药股价下跌近12%。据介绍,UBT251靶向GLP-1、GIP以及胰高血糖素...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10